CERK and breast carcinoma: Moreover, inhibition of the PI3K/Akt pathway or RhoA-dependent protein kinase (ROCK) with the selective inhibitors LY290042 or Y27632, respectively, blocked migration of CERK-overexpressing breast cancer cells, suggesting a relevant role of these pathways in the regulation of CERK-associated breast cancer cell migration; targeting this enzyme may be an important therapeutic strategy in metastatic breast cancer.